POINT Biopharma Announces Successful USD $20M Series A Financing to Bring Precision Radioligand Therapy to Cancer Patients
August 04, 2020 07:30 ET
|
POINT Biopharma
TORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients,...
POINT Biopharma Announces Phase 3 Prostate Cancer Trial
May 12, 2020 06:30 ET
|
POINT Biopharma
TORONTO, May 12, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. is pleased to announce the selection of PSI CRO to manage its phase 3 clinical study of PNT2002, a 177Lu-PSMA radiotherapeutic for the...
POINT Biopharma Announces Global Prostate Oncology Therapeutic Board of Advisors
April 07, 2020 06:00 ET
|
POINT Biopharma
TORONTO, April 07, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. is pleased to announce the formation of its global prostate oncology therapeutic advisory board. The Board, comprised of leading...
POINT Biopharma Announces Manufacturing Leadership and Search for US manufacturing site
March 24, 2020 06:30 ET
|
POINT Biopharma
TORONTO, March 24, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. today announced the appointment of Todd Hockemeyer as Executive Vice President of US Manufacturing Operations. An industrial...
POINT Biopharma and SCINTOMICS Announce License Agreement
March 10, 2020 04:00 ET
|
POINT Biopharma
TORONTO and MUNICH, Germany, March 10, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma Inc. today announced that it has entered into an agreement with SCINTOMICS GmbH for the exclusive use and development...
Point Biopharma Launches With Radiopharmaceutical Development Focus
February 25, 2020 06:45 ET
|
POINT Biopharma
-APPOINTS LEADERSHIP - TORONTO, Feb. 25, 2020 (GLOBE NEWSWIRE) -- POINT Biopharma, a newly formed pharmaceutical company, is combining a seasoned management team with strategic partnerships in...